Incyte Corp
NASDAQ:INCY
Incyte Corp
NASDAQ:INCY
Price:
53.09 USD
0.28%
Market Closed
Updated:
May 3, 2024
Incyte Corp
Revenue
|
Incyte Corp
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Incyte Corp
NASDAQ:INCY
|
Revenue
$3.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
26%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Incyte Corp
Revenue Breakdown
Breakdown by Geography
Incyte Corp
Incyte Corp
|
Total Revenue:
3.7B
USD
|
|
United States:
3.5B
USD
|
|
Europe And Japan:
179.3m
USD
|
Breakdown by Segments
Incyte Corp
Incyte Corp
|
Total Revenue:
3.7B
USD
|
|
Product Revenues, Net:
3.2B
USD
|
|
Product Royalty Revenues:
523.5m
USD
|
|
Jakavi:
367.6m
USD
|
|
Opzelura:
337.9m
USD
|
|
Olumiant:
136.1m
USD
|
|
Jakafi:
122.1m
USD
|
|
Tabrecta:
17.8m
USD
|
|
Milestone And Contract Revenues:
7m
USD
|
See Also
What is Incyte Corp's Revenue?
Revenue
3.7B
USD
3.7B
USD
Based on the financial report for Dec 31, 2023, Incyte Corp's Revenue amounts to 3.7B USD.
What is Incyte Corp's Revenue growth rate?
Revenue CAGR 10Y
26%
26%
Over the last year, the Revenue growth was 9%. The average annual Revenue growth rates for Incyte Corp have been 11% over the past three years , 14% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
